The primary sources for this report include: Recalls (Enforcement Reports Database) The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or not yet classified. While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls
Today, studies estimate that over 80 percent of the personalized compounded GLP-1 drugs now being marketed include added ingredients such as B vitamins (B6, B12, B3)
To find out whether compounded semaglutide or tirzepatide through TrimRx is a fit for your situation, take the intake quiz and a provider will review your health history and walk you through your options
Potentiation and complementation of GLP-1 effects by co-stimulation of GIP (glucose-dependent insulinotropic peptide), glucagon, or amylin and other receptors contribute to additional benefits, opening new horizons in the therapeutic individualization for persons living with obesity
all safety projections are based on shortterm animal data and tiny pilot studies
| Michigan Medicine